#SGOmtg
LightNews LightNews
womenofteal.bsky.social
Attending the #SGOMtg this year? Please help #MultiplyYourImpact by sharing news from the meeting using the #gyncsm hashtag. Thanks!
March 10, 2025 at 12:28 PM
onclive.bsky.social
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer #SGOMtg #SGO25 #gynsm #oncology www.onclive.com/view/puxitat...
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer
Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.
www.onclive.com
March 16, 2025 at 7:33 PM
cancertherapyadv.bsky.social
Mirvetuximab soravtansine improved OS vs chemo in patients with FRα+, platinum-resistant ovarian cancer in the MIRASOL trial. Data were presented at #SGOMtg by Dr Toon Van Gorp of @uzleuven.bsky.social. #SGO2025 #gyncsm shorturl.at/n4n3o
March 17, 2025 at 4:02 PM
onclive.bsky.social
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.
www.onclive.com
January 30, 2025 at 10:52 PM
onclive.bsky.social
ADC Development in Ovarian Cancer: What's Next for FRa and Beyond? #SGOmtg #ovca #oncology www.onclive.com/view/adc-dev...
ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.
www.onclive.com
February 1, 2025 at 12:11 AM
onclive.bsky.social
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
www.onclive.com
March 15, 2025 at 4:53 PM
onclive.bsky.social
Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm
March 15, 2025 at 1:30 PM
onclive.bsky.social
High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma #SGOMtg #gyncsm www.onclive.com/view/high-gr...
High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma
High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.
www.onclive.com
January 31, 2025 at 3:04 AM
onclive.bsky.social
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
www.onclive.com
March 16, 2025 at 5:11 PM
cancertherapyadv.bsky.social
DB-1305/BNT325 demonstrated durable activity in patients with previously treated ovarian cancer, according to data presented at #SGOMtg by Dr Maria Rubinstein of @mskcancercenter.bsky.social. #SGO2025 #gyncsm shorturl.at/tA2bw
Antibody-Drug Conjugate Proves Active in Ovarian Cancer
A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer.
shorturl.at
March 16, 2025 at 9:13 PM
onclive.bsky.social
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.
www.onclive.com
March 15, 2025 at 3:25 PM
sitemancenter.bsky.social
#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Lindsay Kuroki, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8
March 17, 2025 at 1:55 PM
sitemancenter.bsky.social
#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Matthew A. Powell, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8
March 15, 2025 at 8:20 PM
sitemancenter.bsky.social
The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer takes place this weekend, featuring presentations by @washumedicine.bsky.social physicians Matthew Powell, MD, and Lindsay Kuroki, MD. #SGOMtg #AM25IMPACT #SGO2025

Learn more: bit.ly/4hsHDOR
March 13, 2025 at 9:25 PM
researchmatters.bsky.social
Who will be at #SGOMtg? I'm speaking at the Patient Advocate Panel on March 14 about how I've become an accidental advocate (but a committed one!)
#AM25IMPACT
March 12, 2025 at 12:12 AM
onclive.bsky.social
Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #SGO25 #ovca #oncology www.onclive.com/view/ocular-...
Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer
Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.
www.onclive.com
March 18, 2025 at 8:25 PM
onclive.bsky.social
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.
www.onclive.com
March 17, 2025 at 9:42 PM
onclive.bsky.social
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @danafarber.bsky.social #SGOMtg #SGO2025 #gyncsm
www.onclive.com/view/rina-s-...
Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer
The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.
www.onclive.com
March 17, 2025 at 9:23 PM
onclive.bsky.social
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer #SGO2025 #SGOMtg #gyncsm

www.onclive.com/view/dostarl...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.
www.onclive.com
March 17, 2025 at 6:17 PM
onclive.bsky.social
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
#SGO2025 #SGOMtg #gyncsm
www.onclive.com/view/real-wo...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.
www.onclive.com
March 17, 2025 at 6:03 PM
onclive.bsky.social
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.
www.onclive.com
March 17, 2025 at 3:59 PM
onclive.bsky.social
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer #SGOMtg #SGO2025 #ovca

www.onclive.com/view/frontli...
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer
Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.
www.onclive.com
March 16, 2025 at 9:09 PM
onclive.bsky.social
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer @pennmedicine.bsky.social #gyncsm #SGOMtg #SGO2025
www.onclive.com/view/cyclin-...
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer
Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.
www.onclive.com
March 16, 2025 at 4:47 PM
onclive.bsky.social
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
www.onclive.com
March 15, 2025 at 8:17 PM
onclive.bsky.social
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm #oncology
www.onclive.com/view/afurese...
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.
www.onclive.com
March 15, 2025 at 8:12 PM